committee for advanced therapies (cat) · 9. explanatory notes 16 10. list of participants 20. ......

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom

An agency of the European Union

Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

8 December 2017 EMA/CAT/52359/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Advanced Therapies (CAT) Minutes of the meeting on 30-31 October 2017

Health and safety information

In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000508.jsp&mid=WC0b01ac0580028d2a

Committee for Advanced Therapies (CAT) EMA/CAT/52359/20188 /21

Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members, alternates and experts ............ 5

1.2. Adoption of agenda ................................................................................................ 5

1.3. Adoption of the minutes ......................................................................................... 5

1.4. Technical information ............................................................................................. 5

2. Evaluation of ATMPs 5

2.1. Opinions ................................................................................................................. 5

2.2. Oral explanations ................................................................................................... 5

2.2.1. Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue - Orphan - EMEA/H/C/004258 ....................................................................................... 5

2.3. Day 180 list of outstanding issues .......................................................................... 6

2.4. Day 120 list of questions ........................................................................................ 6

2.5. Day 80 assessment reports .................................................................................... 6

2.6. Update on ongoing initial applications .................................................................... 6

2.7. New applications .................................................................................................... 6

2.7.1. Tisagenlecleucel-T - Orphan – H0004090 ...................................................................... 6

2.8. Withdrawal of initial marking authorisation application ......................................... 6

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 ............................................................................................................... 6

2.10. GMP and GCP inspections requests ......................................................................... 7

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .......................................................... 7

2.12. Other Post-Authorisation Activities ........................................................................ 7

2.12.1. Glybera - alipogene tiparvovec - Orphan - EMEA/H/C/002145/SOB/001.7 ......................... 7

2.12.2. Glybera - alipogene tiparvovec - Orphan - EMEA/H/C/002145/SOB/010 ........................... 7

3. Certification of ATMPs 7

3.1. Opinion ................................................................................................................... 8

3.2. Day 60 Evaluation Reports ...................................................................................... 8

3.3. New Applications .................................................................................................... 8

4. Scientific Recommendation on Classification of ATMPs 8

4.1. New requests – Appointment of CAT Coordinator ................................................... 8

4.1.1. Autologous CD34+ cells derived from bone marrow - H0004941 ...................................... 8

4.2. Day 30 ATMP scientific recommendation ................................................................ 8

4.2.1. CD1c (BDCA1)+ myeloid dendritic cells (myDC) - H0004927 ........................................... 8

4.2.2. Genetically modified epithelial cells (factor IX), encapsulated – H0004928 ........................ 8

4.2.3. Stromal vascular fraction (SVF) – H0004926 ................................................................. 9


4.3. Day 60 revised scientific recommendation (following list of questions) ................. 9

4.4. Finalisation of procedure ........................................................................................ 9

4.4.1. Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor’s lipoaspirate – H0004911 ............................................................... 9

4.4.2. Recombinant adeno-associated virus serotype 2/1 vector encoding human β-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906 ...................................... 9

4.4.3. Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905 ..................................................................................... 9

4.4.4. Skin tissue – H0004907 .............................................................................................. 9

4.4.5. Autologous CD34+ cells, freshly isolated – H0004922 .................................................. 10

4.4.6. Autologous dental pulp stem cells (DPSC), freshly isolated – H0004923 ......................... 10

4.4.7. Cultured dental pulp stem cells (DPSC) – H0004924 .................................................... 10

4.5. Follow-up and guidance ........................................................................................ 10

5. Scientific Advice 10

5.1. New requests – appointment of CAT Rapporteurs ................................................ 10

5.2. CAT reports ........................................................................................................... 10

5.3. List of Issues ........................................................................................................ 11

5.4. Finalisation of SA procedures ............................................................................... 11

6. Pre-Authorisation Activities 11

6.1. Paediatric investigation plans ............................................................................... 11

6.2. ITF briefing meetings in the field of ATMPs .......................................................... 11

6.3. Priority Medicines (PRIME) – Eligibility requests .................................................. 11

6.3.1. Month 0 - Start of the procedure ............................................................................... 11

6.3.2. Month 1 – Discussion of eligibility .............................................................................. 11

6.3.3. Month 2 – Recommendation of eligibility..................................................................... 11

6.3.4 Month 3 – Nomination of Rapporteurs ........................................................................ 11

6.3.5 Ongoing support ...................................................................................................... 11

7. Organisational, regulatory and methodological matters 11

7.1. Mandate and organisation of the CAT ................................................................... 11

7.1.1. CAT membership ..................................................................................................... 11

7.1.2. Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017 ............. 12

7.1.3. User manual on CxMP/EMA external representation ..................................................... 12

7.1.4. Rapporteurship bidding process for evaluations of centralised procedures ....................... 12

7.2. Coordination with EMA Scientific Committees....................................................... 12

7.2.1. Committee for Medicinal Products for Human Use (CHMP) ............................................ 12

7.2.2. Scientific Co-ordination Board (SciCoBo) – meeting of 21 September 2017 ..................... 12

7.2.3. Cell based ATMP nomenclature .................................................................................. 12

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ......... 13


7.3.1. Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement of animal testing) in regulatory testing of medicinal products ................................................................................................................. 13

7.3.2. Scientific Advice Working Party (SAWP) ...................................................................... 13

7.4. Cooperation within the EU regulatory network ..................................................... 13

7.4.1. EU Network Pharmacovigilance Oversight Group (EU-POG) (former ERMS FG) ................. 13

7.5. Cooperation with international regulators ............................................................ 14

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA................................... 14

7.6. CAT work plan ...................................................................................................... 14

7.6.1. CAT 2018 work plan ................................................................................................. 14

7.6.2. Registry requirements for chimeric antigen receptor T (CAR-T) cells .............................. 14

7.6.3. Expert meeting on genome editing, EMA, London, UK, 18 October 2017 ......................... 14

7.7. Planning and reporting ......................................................................................... 15

7.7.1. European Commission and European Medicines Agency Action Plan on ATMPs ................. 15

7.8. Others .................................................................................................................. 15

8. Any other business 15

9. Explanatory notes 16

10. List of participants 20


1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 30-31 October 2017 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 4-6 October 2017 meeting were adopted.

1.4. Technical information

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

2.2.1. Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue - Orphan - EMEA/H/C/004258

Tigenix, S.A.U.; treatment of complex perianal fistula(s)

Scope: Oral explanation

Action: Oral explanation to be held on 30 October 2017 at 13:30


The Rapporteurs presented the assessment of the responses to the list of outstanding issues. CAT was informed of the outcome of the BWP discussion .

Further to the CAT initial discussion the applicant was invited for an oral explanation .

After the oral explanation, in absence of the applicant, CAT further discussed.

The applicant will provided response to the outstanding issues, the updated product information and RMP, and the letter of commitments. The final discussion, final vote and the adoption of the opinion will take place in the December 2017 CAT meeting.

Post meeting note: the second list of outstanding issues together with a specific timetable will be adopted by the CAT via written procedure.

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

2.7.1. Tisagenlecleucel-T - Orphan – H0004090

Novartis Europharm Ltd.; Indicated for: -the treatment of paediatric and young adult patients 3 to 25 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). - the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant

Scope: Rapporteurs’ recommendation on the request for accelerated assessment

Action: for adoption

2.8. Withdrawal of initial marking authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items


2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

2.12. Other Post-Authorisation Activities

2.12.1. Glybera - alipogene tiparvovec - Orphan - EMEA/H/C/002145/SOB/001.7

uniQure biopharma B.V.; Indicated for the long term correction of lipoprotein lipase deficiency, to control or abolish symptoms and prevent complications in adult patients clinically diagnosed with lipoprotein lipase deficiency (LPLD)

Rapporteur: Christiane Niederlaender; Co-Rapporteur: Egbert Flory; CHMP Coordinators: Greg Markey, Jan Mueller-Berghaus

Scope: proposals for amendments to the registry protocol

Action: for information

Note: a CAT written procedure was finalised on 19 October 2017 to endorse the Rapporteur’s assessment report. The MAH is aiming to keep the registry active after the expiry of the MA (25 October 2017).

The information was noted.

2.12.2. Glybera - alipogene tiparvovec - Orphan - EMEA/H/C/002145/SOB/010

uniQure biopharma B.V.; Indicated for the long term correction of lipoprotein lipase deficiency, to control or abolish symptoms and prevent complications in adult patients clinically diagnosed with lipoprotein lipase deficiency (LPLD)

Rapporteur: Christiane Niederlaender; Co-Rapporteur: Egbert Flory; CHMP Coordinators: Greg Markey, Jan Mueller-Berghaus

Scope: monitoring of immune response: validation of assays


Note: in view of the expiry of the MA, CAT to consider adoption of the outcome of this post-authorisation measure at the November 2017 CAT meeting (instead of the December 2017 meeting).

CAT adopted the outcome of this post-authorisation measure.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.


3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous CD34+ cells derived from bone marrow - H0004941

Intended for the improvement of neurologic function in patients with non-lacunar acute ischemic stroke infarctions

Scope: appointment of CAT Coordinator and adoption of timetable


Nominations were received. The CAT member was appointed as CAT coordinator

4.2. Day 30 ATMP scientific recommendation

4.2.1. CD1c (BDCA1)+ myeloid dendritic cells (myDC) - H0004927

Intended for the treatment of patients with advanced, pretreated solid tumours with injectable metastases

Scope: scientific recommendation


CAT discussed and adopted the ATMP classification report. CAT Secretariat to send the draft scientific recommendation to the European Commission for comments by 17 November 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Genetically modified epithelial cells (factor IX), encapsulated – H0004928

Intended for the treatment of haemophilia B



CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 17 November 2017.


The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. Stromal vascular fraction (SVF) – H0004926

Intended to diminish cancer-related lymphedemia in breast cancer patients



CAT discussed the ATMP classification report. CAT decided that additional information is needed from the applicant before concluding on this classification request.

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor’s lipoaspirate – H0004911

Intended to help post - myocardial infarction patients in restoring cardiac function to repair the underlying myocardium damage

Scope: no comments received by the European Commission. Final ATMP scientific recommendation


4.4.2. Recombinant adeno-associated virus serotype 2/1 vector encoding human β-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906

Intended for the treatment of Tay-Sachs disease & Sandhoff disease monosialic ganglioside 2 (GM2) gangliosidosis



4.4.3. Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905

Intended for the treatment of hypercholesterolaemia caused by homozygous mutations in the low density lipoprotein receptor (LDLR) gene



4.4.4. Skin tissue – H0004907

Intended for the treatment of patients with acute complex skin loss


Scope: comments received by the European Commission. Clarification included in section 2 of the ATMP scientific recommendation. Final ATMP scientific recommendation


4.4.5. Autologous CD34+ cells, freshly isolated – H0004922

Cells to be used to contribute to the regeneration of soft and hard tissues of temporomandibular joints through their immunological action



4.4.6. Autologous dental pulp stem cells (DPSC), freshly isolated – H0004923

Intended for the regeneration of soft and hard tissues of temporomandibular joints



4.4.7. Cultured dental pulp stem cells (DPSC) – H0004924

Intended for the regeneration of soft and hard tissues of temporomandibular joints



4.5. Follow-up and guidance

No items

5. Scientific Advice


5.1. New requests – appointment of CAT Rapporteurs

Timetable: -Final Briefing Package: 22.11.17 -Start of the procedure at SAWP: 27-30.11.17 -CAT report due by: 01.12.17 -CAT recommendation: 08.12.17

5.2. CAT reports


5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities


6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment: Procedure start: 26.10.17. SAWP recommendation: 30.11.17. CAT recommendation: 08.12.17. CHMP adoption of report and final recommendation: 14.12.17.

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4 Month 3 – Nomination of Rapporteurs

6.3.5 Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Scope: membership changes

Finland: Heli Suila – member nomination started on 07 October 2017 Lithuania: Vitalis Briedis – alternate membership started on 19 October 2017


Lithuania: Jolanta Gulbinovič – alternate membership ended on 18 October 2017


The CAT chair welcomed the new member from Finland, who attended the CAT meeting for the first time.

7.1.2. Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017

CAT Strategic Review & Learning meeting (SRLM) will take place in Tallinn, Estonia on 15-17 November 2017 under the auspices of the Estonian Presidency of the Council of the European Union

Scope: final programme


The final programme was noted.

7.1.3. User manual on CxMP/EMA external representation

Action: For information

CAT noted the information on the CAT external representation in conference and external scientific meetings and the disclaimer to be included in their presentations.

7.1.4. Rapporteurship bidding process for evaluations of centralised procedures

Scope: a new 2-stage bidding process for Rapporteurships

Action: For information

CAT noted the information on the new bidding process (which is already in practice at CHMP for the last 2 months). The aim of this new process is to facilitate the setting up of multi-national assessment teams.

7.2. Coordination with EMA Scientific Committees

7.2.1. Committee for Medicinal Products for Human Use (CHMP)

Scope: Summary of Outcomes (SoO) for the October 2017 meeting


The information was noted.

7.2.2. Scientific Co-ordination Board (SciCoBo) – meeting of 21 September 2017

CAT: Martina Schüßler-Lenz

Scope: feedback on the outcome of the SciCoBo meeting that took place in September 2017


The CAT chair provided a short feedback on the discussion at the September SciCoBo meeting.

7.2.3. Cell based ATMP nomenclature

Scope: guidance on the terminology for cell-based medicinal products (currently applied by the COMP)Action: for information


CAT noted the information on the terminology used by COMP for cell-based orphan medicinal product designations. This is not a formal or enforced nomenclature, and has no link with the WHO proposed nomenclature for cell-based products.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement of animal testing) in regulatory testing of medicinal products

Scope: -review of EMA Guidelines considering 3Rs - report on actions taken -overview of comments received - JEG 3Rs - best practice Action: for comments by 10 November 2017 Note: CAT adopted in September 2016 the comments to the ATMP related entries in the tables included in the reflection paper and agreed on the proposed amendments. The report and overview of comments documents will be submitted to the CHMP and CVMP in December 2017/January 2018 for adoption and publication. EMA presented the two documents and provide background on the exercise undertaken to review all EMA guidance document in relation to the 3R principle. The documents will be endorsed at the December CAT meeting.

7.3.2. Scientific Advice Working Party (SAWP)

Martina Schüßler-Lenz

Scope: Re-examination of the SAWP composition - call for interest to become one of the CAT representatives in the SAWP.

Action: expression of interest to be sent to CAT secretariat by 27 October 2017

Note: the role and responsibilities: they will act as liaisons between the CAT and the SAWP and act as SAWP coordinators for (a limited number) of scientific advices. The joint CAT-SAWP member will have need to access to experts in their agency / organisation to respond to questions related of the quality, non-clinical and clinical development. The CHMP at its December 2017 meeting will adopt the new composition of the SAWP.

CAT noted the nominations received. No decision has been taken yet .

7.4. Cooperation within the EU regulatory network

7.4.1. EU Network Pharmacovigilance Oversight Group (EU-POG) (former ERMS FG)

Scope: nomination of a CAT representative to the EU-POG

Action: for nomination

Nominations received: Corina Spreitzer (AT)

Note: -Overview: the EU-POG (formerly known as the European Risk Management Strategy Facilitation Group) was established as a permanent Working Group in 2005.The group aim is to develop a European Strategy for risk management, built on the National Competent Authorities (NCA’s) resources and expertise, and incorporating the EMA’s role in the coordination and the supervision of products authorised through the EU.


-Mandate: ‘To prioritise issues for HMA and EMA Management Board consideration, on criteria based on public health and risk to operation of the EU network pharmacovigilance system’. -Meeting cycle: bi-monthly by teleconference or face to face meetings when needed.

http://www.hma.eu/ermsfg.html

CAT nominated Corina Spreitzer to join the EU-POG as CAT representative.

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with FDA, Health Canada and PMDA

The teleconference will take place right after the end of the second day of the plenary meeting


Scope: draft agenda


The agenda for the ATMP cluster teleconference was agreed.

7.6. CAT work plan

7.6.1. CAT 2018 work plan


Scope: CAT 2018 work plan


Draft 4 of the CAT 2018 work plan was presented and discussed. Adoption was postponed until the December 2017 CAT meeting to allow further reflection on the proposed topic on comparability for ATMPs (i.e. what ATMP types to be addressed and the order to develop guidance for these different types).

7.6.2. Registry requirements for chimeric antigen receptor T (CAR-T) cells


Scope: feedback on the proposed actions


Note: this will be a cross-committee activity, involving members/experts from CAT, SAWP, PRAC, CHMP and PDCO.

The CAT chair presented the proposal.

7.6.3. Expert meeting on genome editing, EMA, London, UK, 18 October 2017

CAT: Martina Schüßler-Lenz, Bernd Gansbacher, Paolo Gasparini

Scope: oral feedback on the expert meeting


An oral feedback was provided from the discussions in the Genome editing meeting that took place on 18 October 2017. During the upcoming Strategic Review and Learning meeting (see 7.1.2.), CAT members will discuss further how to incorporate the novel scientific issues in existing and/or new guidance. Further reflection will also have to take place on regulatory considerations.

http://www.hma.eu/ermsfg.html


7.7. Planning and reporting

7.7.1. European Commission and European Medicines Agency Action Plan on ATMPs


Scope: The ‘European Commission and European Medicines Agency Action Plan on ATMPs’ has been published on 20 October 2017


CAT noted the published action plan.

7.8. Others

8. Any other business

No items

Date of next CAT meeting: 06-08 December 2017

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/10/WC500237029.pdf


9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

http://www.google.co.uk/url?url=http://www.pmda.go.jp/english/&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwi08422gdXLAhVGuhoKHUlUD9MQFggVMAA&usg=AFQjCNEM7RXAZJ9HNzWc1iLLlHkUFC6BXQ


SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SB: Significant benefit

SR: Summary Report

SWP: Scientific Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a Day 120 list of questions (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (Ongoing evaluation procedures). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/02/WC500070340.pdf


evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000300.jsp&mid=WC0b01ac058007f4bd

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000296.jsp&mid=WC0b01ac058007f4bc

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049.jsp&mid=WC0b01ac05800229b9


Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000334.jsp&mid=WC0b01ac05800ba1d9

http://www.ema.europa.eu/


10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 30-31 October 2017 meeting.

Name Role Member state or affiliation

Outcome restriction following evaluation of e-DoI

Topics on agenda for which restrictions apply

Martina Schüssler-Lenz

Chair Germany No interests declared N/A

Corina Spreitzer

Alternate Austria No interests declared N/A

Claire Beuneu Member Belgium No interests declared N/A Belaïd Sekkali Alternate Belgium No interests declared N/A Rozalina Kulaksazova

Member Bulgaria No interests declared N/A

Ivica Malnar Alternate Croatia No interests declared N/A Marina Ieridi Member Cyprus No interests declared N/A Tomáš Boráň Alternate Czech Republic No interests declared N/A Anne Pastoft Alternate Denmark No interests declared N/A Toivo Maimets Member Estonia No interests declared N/A Heli Suila Member Finland No interests declared N/A Olli Tenhunen Alternate Finland No interests declared N/A Violaine Closson

Member France No interests declared N/A

Jan Mueller-Berghaus

Member Germany No interests declared N/A

Egbert Flory Alternate – via TC

Germany No interests declared N/A

Angeliki Roboti

Alternate Greece No interests declared N/A

Balázs Sarkadi Alternate Hungary No interests declared N/A Maura O'Donovan

Member Ireland No interests declared N/A

Paolo Gasparini

Member Italy No interests declared N/A

Romaldas Mačiulaitis

Member (CHMP member)

Lithuania No restrictions applicable to this meeting

N/A

John J. Borg Member (CHMP member)

Malta No interests declared N/A

Johannes Hendrikus Ovelgönne

Member Netherlands No interests declared N/A

Helga Haugom Olsen

Member Norway No interests declared N/A

Rune Kjeken Alternate Norway No restrictions applicable to this meeting

N/A

Dariusz Śladowski

Member Poland No restrictions applicable to this meeting

N/A

Margarida Menezes-Ferreira

Alternate (to CHMP representative)

Portugal No interests declared N/A

Simona Badoi Member Romania No interests declared N/A Mikuláš Member Slovakia No interests declared N/A


Name Role Member state or affiliation

Outcome restriction following evaluation of e-DoI

Topics on agenda for which restrictions apply

Hrubiško Metoda Lipnik-Stangelj

Member Slovenia No interests declared N/A

Marcos Timón Alternate, replacing CHMP member

Spain No interests declared N/A

Lennart Åkerblom

Member Sweden No interests declared N/A

Björn Carlsson Alternate Sweden No interests declared N/A Christiane Niederlaender

Member United Kingdom No interests declared N/A

Marc Turner Member Healthcare Professionals' Representative

No restrictions applicable to this meeting

N/A

Bernd Gansbacher

Member Healthcare Professionals' Representative

No interests declared N/A

Kieran Breen Member Patients' Representative


N/A

Mariëtte Driessens

Member Patients' Representative


N/A

Erik Briers Alternate Patients' Representative


N/A

Tomas Salmonson

Expert – via Adobe*

Sweden No interests declared N/A

A representative from the European Commission attended the meeting Meeting run with support from relevant EMA staff

* Experts were only evaluated against the agenda topics or activities they participated in.

committee for advanced therapies (cat) · 9. explanatory notes 16 10. list of participants 20. ......

Documents